Home » Topics » BioWorld Science

BioWorld Science
RSS

RUNX1 targeting shows promise for treating aggressive PDAC

March 3, 2022

Researchers present CX-10759 anti-IgE antibody for hypersensitivity

March 3, 2022

Targeting PD-1/PD-L1 pathway prevents allergic immune response

March 2, 2022

Neuropathy may unify disparate long COVID symptoms

March 2, 2022

HuR ablation ameliorates allergen-induced asthmatic symptoms

March 2, 2022

LIGHT mediates esophageal remodeling in murine model of eosinophilic esophagitis

March 2, 2022

Quanterix collaborates with Lilly on diagnosis and treatment of Alzheimer's disease

March 2, 2022

JAK1 activation of sensory neurons suppresses lung inflammation

March 2, 2022

HLA-DPB1*05:01 allele predicts nonresponse to SLIT in allergic rhinitis

March 2, 2022

SIGLEC-6 targeting inhibits human mast cell degranulation and anaphylaxis

March 2, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...